Connect with us

Hi, what are you looking for?

Friday, Sep 22, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


CBD cocrystal variation superior to CBD in treating some mental illnesses: Artelo Biosciences

The cannabinoid variation could potentially have a major role in the depression and anxiety market, worth an estimated US$11 billion

Chatham-Kent Police bust $6.1M worth of cannabis plants
Cannabis grown by BC Green Pharmaceuticals. Photo by Rowan Dunne

The California-based company Artelo Biosciences, Inc. (Nasdaq: ARTL) says it has developed a novel variation of cannabidiol (CBD) that has shown promising results in animal studies indicating that it may be a superior alternative to the standard widely-used cannabinoid.

The company presented findings on the ART12.11 cocrystal CBD composition on Sunday at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario. Artelo says the patented CBD variation has shown superior bioavailability and efficacy for the treatment of anxiety, PTSD and depression in preclinical studies.

Artelo’s President and CEO Gregory D. Gorgas says the company believes the cannabinoid variation could potentially have a major role in the depression and anxiety market, worth an estimated US$11 billion.

Rodent studies on ART12.11 at the University of Western Ontario showed that the drug had strong anxiety-reducing and anti-depressive effects that significantly outperformed standard CBD.

“A multiple-dose pharmacokinetic animal study conducted at different research laboratories showed that this novel cocrystal form of CBD demonstrated improved pharmaceutical properties, including solubility and dissolution, and delivered higher plasma levels of CBD and its major metabolite compared to CBD alone,” said Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo.

Read more: Less than 25% of U.S. cannabis businesses were profitable in Q4, 2022: Whitney Economics

Read more: Heritage Cannabis ships first batch of live resin vape cartridges to Australia

The Toronto symposium is currently ongoing until June 29, features over 75 oral presentations and focuses on providing a forum for cannabinoid researchers to meet and discuss their findings. The ICRS is composed of 40 countries and has over 650 members from around the globe.

In addition to depression, PTSD and anxiety, Artelo is actively involved in developing treatments for other conditions like anorexia, inflammation and cancer.

The company had US$15.5 million cash on hand at the end of Q1 this year and 2.85 million issued and outstanding common shares at the end of the quarter.

Artelo’s shares stayed flat Monday at US$1.95 on the Nasdaq Stock Exchange.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Ovation will provide Planet 13 with manufacturing, sales and marketing rights for its topical/transdermal products in Nevada


Lucy also expects to add $5 million of EBITDA to its financial results next year from the deal


The non-profit is organizing a rally at the Manitoba Legislative Building on Friday


Avextra’s cannabis-based medicines are now present in six European markets